See the DrugPatentWatch profile for Inmazeb
What is Inmazeb (inebilizumab-cdon) and what is it used for?
Inmazeb is a prescription medicine used to treat Ebola virus disease in adults and children, including people with the Zaire Ebola species. It is given in a hospital setting as an intravenous infusion [1].
How does Inmazeb work?
Inmazeb is a combination of three monoclonal antibodies that bind to the Ebola virus and help block infection [1].
Who can receive Inmazeb?
It is used for patients with confirmed Ebola virus disease (Zaire ebolavirus) who are under the care of clinicians managing Ebola treatment. Use is generally tied to the specific indications and dosing guidance in the product information [1].
How is Inmazeb given (dose and schedule)?
Inmazeb is administered by intravenous infusion in a hospital. The exact dosing and infusion schedule follow the prescribing information for the product [1].
What side effects are associated with Inmazeb?
Possible adverse reactions include infusion-related reactions and other treatment-emergent effects reported for monoclonal antibody therapies. Clinicians weigh risks and benefits based on the patient’s condition, comorbidities, and supportive care needs during Ebola treatment [1].
Is Inmazeb a cure, and how effective is it?
Inmazeb is intended to improve outcomes in Ebola virus disease when used in appropriate patients as part of Ebola care. Treatment effectiveness is based on clinical evaluation summarized in the product information [1].
Where can people access Inmazeb, and how is it regulated?
Inmazeb is a regulated prescription product (approval and labeling depend on jurisdiction). Access is typically through health systems and specialized treatment centers managing Ebola cases [1].
Sources
[1] FDA label for INMAZEB (inebilizumab-cdon). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm